Literature DB >> 288932

Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat.

H N McCullough, R L Juliano.   

Abstract

beta-Cytosine arabinoside (Ara-C) in free and liposome encapsulated form was administered to Wistar rats by intratracheal institution. Free [3H]Ara-C administered in this manner rapidly left the lung and entered the systemic circulation. Liposome-encapsulated [3H]Ara-C persisted in the lung for a long period, with little redistribution to other tissues. Liposomes administered via the trachea became widely distributed throughout the lung air spaces, as evidenced by the histochemical localization of liposomes containing horse-radish peroxidase. Free Ara-C (5 mg/kg) administered into the trachea effectively suppressed macromolecular incorporation of [14C]thymidine ([14C]dThd) in the bone marrow and gut as well as in the lung. Liposome-encapsulated Ara-C (5 mg/kg) effectively suppressed macromolecular incorporation of [14C]dThd in the lung but had little effect on this process in the gut and bone marrow. Our results suggest that liposome-encapsulated Ara-C may be able to produce a local pharmacologic effect within the lung without producing adverse side effects in other tissues. This observation may be relevant to the chemotherapy of pulmonary metastases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 288932     DOI: 10.1093/jnci/63.3.727

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  6 in total

1.  Liposomes for controlled delivery of drugs to the lung.

Authors:  K M Taylor; J M Newton
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

2.  The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.

Authors:  Aileen Gibbons; Danielle Padilla-Carlin; Ciara Kelly; Anthony J Hickey; Clifford Taggart; Noel G McElvaney; Sally-Ann Cryan
Journal:  Pharm Res       Date:  2011-06-07       Impact factor: 4.200

3.  Use of monoclonal antibodies and liposomes to improve drug delivery. Present status and future implications.

Authors:  G Gregoriadis
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

4.  A dry powder formulation of liposome-encapsulated recombinant secretory leukocyte protease inhibitor (rSLPI) for inhalation: preparation and characterisation.

Authors:  Aileen Gibbons; Noel G McElvaney; Sally-Ann Cryan
Journal:  AAPS PharmSciTech       Date:  2010-09-15       Impact factor: 3.246

5.  Nebulization of liposomes. I. Effects of lipid composition.

Authors:  R W Niven; H Schreier
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

Review 6.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.